Skip to content

Evaluation of prednisolone efficacy in the treatment of cervical radiculopathy

Survey of therapeutic effect of oral prednisolone in compression of placebo in cervical radiculopathy treatment

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138801211804N1
Enrollment
60
Registered
2010-10-23
Start date
2009-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical radiculopathy. Nerve root and plexus compressions in spondylosis

Interventions

Intervention 1: First group: Acetaminophen 325 milligram in 3 doses daily and Prednisolone 50 milligram oral, daily for 5 days and then will be tapered in 5 days. Intervention 2: Second group: Acetami
Treatment - Drugs
Placebo
First group: Acetaminophen 325 milligram in 3 doses daily and Prednisolone 50 milligram oral, daily for 5 days and then will be tapered in 5 days
Second group: Acetaminophen 325 milligram in 3 doses daily and placebo for 5 days and then will be tapered in 5 days

Sponsors

Private
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1- Age 60-18 years. 2- Arm and neck pain consistent with cervical radiculopathy. 3- Neck disability scale (NDI) at least 15 (moderate disability). 4- The onset of symptoms between 2 weeks to 1 month. 5- No chronic use of corticosteroid. 6- No a history of previous surgery of cervical spine. Exclusion criteria: 1- Patients with immunosupression. 2- Red flag of tumor and clinical infection. 3- Symptoms of myelopathy. 4- Liver failure. 5- Schizophrenia. 6- Pregnancy and lactation. 7- Diabetes. 8- Osteoporosis. 9- Glaucoma. 10- Peptic ulcer. 11- Normal EMG after one month.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: week. Method of measurement: NDI (neck disability index) and VRS (visual rating scale).

Secondary

MeasureTime frame
Drug side effect. Timepoint: week. Method of measurement: patient report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Ghasemi

Isfahan university of medical sciences

m_ghasemi@med.mui.ac.ir+98 31 1235 0004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026